| Entry |
|
|---|
| Name |
Loxapine (USAN/INN);
Adasuve (TN) |
|---|
| Product |
|
|---|
| Formula |
C18H18ClN3O
|
|---|
| Exact mass |
327.1138
|
|---|
| Mol weight |
327.808
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01644 CYP2D6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00897): | D02340<US> D00794<US> |
|
|---|
| Efficacy |
Minor tranquilizer, Dopamine D2 receptor antagonist, Serotonin receptor antagonist |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544], CYP3A4 [HSA: 1576], CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH01 Loxapine
D02340 Loxapine (USAN/INN) <US>
USP drug classification [BR:br08302]
Antipsychotics
1st Generation/Typical
Loxapine
D02340 Loxapine (USAN/INN)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00897 Loxapine
D02340 Loxapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00897 Loxapine
D02340 Loxapine
DG01644 CYP2D6 substrate
DG00897 Loxapine
D02340 Loxapine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00897 Loxapine
D02340 Loxapine
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D02340 Loxapine (USAN/INN) <US>
Serotonin
HTR2A
D02340 Loxapine (USAN/INN) <US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02340
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02340
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00897 Loxapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00897 Loxapine
DG01644 CYP2D6 substrate
DG00897 Loxapine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00897 Loxapine
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 23
1 C2y C 14.6234 -16.0394
2 C8y C 13.7813 -14.9298
3 C8y C 14.1165 -13.5730
4 O2x O 15.3775 -12.9949
5 N2x N 16.0292 -16.0646
6 C8y C 16.6311 -13.6172
7 C8y C 16.9176 -14.9859
8 C8x C 13.1094 -12.6046
9 C8x C 11.7674 -12.9927
10 C8y C 11.4322 -14.3495
11 C8x C 12.4393 -15.3176
12 C8x C 18.2488 -15.4230
13 C8x C 19.2930 -14.4886
14 C8x C 19.0066 -13.1199
15 C8x C 17.6752 -12.6828
16 X Cl 10.0674 -14.7439
17 N1y N 13.9889 -17.2891
18 C1x C 12.5873 -17.2891
19 C1x C 11.8865 -18.5029
20 N1y N 12.5873 -19.7169
21 C1x C 13.9889 -19.7169
22 C1x C 14.6897 -18.5029
23 C1a C 11.8803 -20.9409
BOND 26
1 3 4 1
2 1 5 2
3 4 6 1
4 2 3 1
5 5 7 1
6 1 2 1
7 6 7 1
8 3 8 2
9 8 9 1
10 9 10 2
11 10 11 1
12 2 11 2
13 7 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 6 15 2
18 10 16 1
19 1 17 1
20 17 18 1
21 18 19 1
22 19 20 1
23 20 21 1
24 21 22 1
25 17 22 1
26 20 23 1
|
|---|
